Global Dyspepsia Market- Industry Analysis and forecast 2019 – 2027: By Diagnosis, Treatment, End-User and Region.

Global Dyspepsia Market- Industry Analysis and forecast 2019 – 2027: By Diagnosis, Treatment, End-User and Region.

Market Scenario

Global Dyspepsia Market size was valued at US$ XX Mn. in 2019 and the total revenue is expected to grow at 4.01% from 2019 to 2027, reaching nearly US$ XX Mn.   Global Dyspepsia Market The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Dyspepsia is also called as stomachache is gastroenterology disorders characterized by persistent or recurrent pain. It is usually a sign of an underlying condition like GERD (gastroesophageal reflux disease), gallbladder and ulcers disease. The dyspepsia patients may experience a burning sensation in the stomach part, severe stomach pain, vomiting, and nausea. Dyspepsia is a very general symptom, accounting for amid 1.2% and 4% of all discussions in primary care in the United Kingdom. As per the National Institute of Diabetes & Digestive and Kidney Diseases article, it is projected 1 in every 4 people in the U.S. diagnosed with dyspepsia yearly. This rising incidence of dyspepsia globally, irregular intake habits and launch of novel products are the major factors that reinforce the dyspepsia market position. Moreover, in 2018, the American Cancer Society estimated nearly 26,240 new cases of stomach cancer to be analyzed. On the other hand, high costs related to diagnostic tests and cut-throat competition between market companies are some of the factors that are expected to restrict the dyspepsia market growth over 2019-2027. Likewise, the report contains a detailed study of factors that will drive and restrain the growth of the dyspepsia market globally. The report offers a brief analysis of the major regions in the dyspepsia market, namely, APAC, Europe, North America, South America, and the MEA. North America dyspepsia market was valued US$ XX.15 Mn. in 2019 and is expected to reach a value of US$ XX.67 Mn. by 2027, with a CAGR of XX.36% during 2019-2027. This is credited to favourable reimbursement, technological advancements. Consistent with the Centers for Disease Control and Prevention, nearly 3 million people suffered from ulcerative colitis in 2015. It causes infection of the digestive area which might lead to dyspepsia. By End-User, the segment is divided into hospitals and clinics, ambulatory surgical centres, pharmacies, diagnostic centres, and others. Among these, the hospitals and clinics segment held the largest market share of XX% in 2019 and is projected to grow at the highest CAGR of XX.23% to reach US$ XX Mn by 2027 because of the growing prevalence of digestive diseases. The MMR report covers the segments in the dyspepsia market such as diagnosis, treatment, and end-user. The MMR report also focuses on the major leading industry players globally of dyspepsia market providing information like company profiles, production, and revenue. In 2018, Eisai company has launched Cidine i.e. cinitapride hydrogen tartrate, a stomach prokinetic agent in China for the treatment of mild to moderate functional dyspepsia. The launch is set to change the treatment scenario for dyspepsia suffering patients. The objective of the report is to present a comprehensive analysis of the Global Dyspepsia Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Dyspepsia Market dynamics, structure by analyzing the market segments and projects the Global Dyspepsia Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Dyspepsia Market make the report investor’s guide.

Scope of the Global Dyspepsia Market

Global Dyspepsia Market, by Diagnosis

• Blood Tests • Breath Tests • Stool Tests • Endoscopy • X-ray • CT scan • Others

Global Dyspepsia Market, by Treatment

• Antacids • Antibiotics • H2 Blockers • Proton Pump Inhibitors (PPIs) • Prokinetics • Psychological Therapies • Others

Global Dyspepsia Market, by End-User

• Hospitals and clinics • Ambulatory surgical centers • Pharmacies • Diagnostic centers • Others

Global Dyspepsia Market, by Region

• Asia Pacific  India  China  Japan  South Korea  Australia  Indonesia  Malaysia  Vietnam  Rest of Asia • North America  U.S.  Canada • Europe  U.K  Germany  France  Russia  Spain  Italy  Sweden • South America  Mexico  Brazil  Rest of South America • Middle East & Africa  GCC  South Africa  Rest of MEA

Key players operating in Global Dyspepsia Market

• AstraZeneca • GlaxoSmithKline • Takeda Pharmaceutical Company • Johnson & Johnson • Jiangsu Aosaikang Pharma • Eisai Co., Ltd. • Abbott Laboratories • Salix Pharmaceuticals • Bayer AG • Boehringer Ingelheim GmbH • Sanofi • Allergan Plc • Cadila Pharmaceuticals • Pfizer

Table of Contents

Global Dyspepsia Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Dyspepsia Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Dyspepsia Market Analysis and Forecast 6.1. Dyspepsia Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Dyspepsia Market Analysis and Forecast, By End-User 7.1. Introduction and Definition 7.2. Key Findings 7.3. Dyspepsia Market Value Share Analysis, By End-User 7.4. Dyspepsia Market Size (US$ Bn) Forecast, By End-User 7.5. Dyspepsia Market Analysis, By End-User 7.6. Dyspepsia Market Attractiveness Analysis, By End-User 8. Global Dyspepsia Market Analysis and Forecast, By Treatment 8.1. Introduction and Definition 8.2. Key Findings 8.3. Dyspepsia Market Value Share Analysis, By Treatment 8.4. Dyspepsia Market Size (US$ Bn) Forecast, By Treatment 8.5. Dyspepsia Market Analysis, By Treatment 8.6. Dyspepsia Market Attractiveness Analysis, By Treatment 9. Global Dyspepsia Market Analysis and Forecast, By Diagnosis 9.1. Introduction and Definition 9.2. Key Findings 9.3. Dyspepsia Market Value Share Analysis, By Diagnosis 9.4. Dyspepsia Market Size (US$ Bn) Forecast, By Diagnosis 9.5. Dyspepsia Market Analysis, By Diagnosis 9.6. Dyspepsia Market Attractiveness Analysis, By Diagnosis 10. Global Dyspepsia Market Analysis, by Region 10.1. Dyspepsia Market Value Share Analysis, by Region 10.2. Dyspepsia Market Size (US$ Bn) Forecast, by Region 10.3. Dyspepsia Market Attractiveness Analysis, by Region 11. North America Dyspepsia Market Analysis 11.1. Key Findings 11.2. North America Dyspepsia Market Overview 11.3. North America Dyspepsia Market Value Share Analysis, By End-User 11.4. North America Dyspepsia Market Forecast, By End-User 11.4.1. Hospitals and clinics 11.4.2. Ambulatory surgical centers 11.4.3. Pharmacies 11.4.4. Diagnostic centers 11.4.5. Others 11.5. North America Dyspepsia Market Value Share Analysis, By Treatment 11.6. North America Dyspepsia Market Forecast, By Treatment 11.6.1. Antacids 11.6.2. Antibiotics 11.6.3. H2 Blockers 11.6.4. Proton Pump Inhibitors (PPIs) 11.6.5. Prokinetics 11.6.6. Psychological Therapies 11.6.7. Others 11.7. North America Dyspepsia Market Value Share Analysis, By Diagnosis 11.8. North America Dyspepsia Market Forecast, By Diagnosis 11.8.1. Blood Tests 11.8.2. Breath Tests 11.8.3. Stool Tests 11.8.4. Endoscopy 11.8.5. X-ray 11.8.6. CT scan 11.8.7. Others 11.9. North America Dyspepsia Market Value Share Analysis, by Country 11.10. North America Dyspepsia Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Dyspepsia Market Analysis, by Country 11.12. U.S. Dyspepsia Market Forecast, By End-User 11.12.1. Hospitals and clinics 11.12.2. Ambulatory surgical centers 11.12.3. Pharmacies 11.12.4. Diagnostic centers 11.12.5. Others 11.13. U.S. Dyspepsia Market Forecast, By Treatment 11.13.1. Antacids 11.13.2. Antibiotics 11.13.3. H2 Blockers 11.13.4. Proton Pump Inhibitors (PPIs) 11.13.5. Prokinetics 11.13.6. Psychological Therapies 11.13.7. Others 11.14. U.S. Dyspepsia Market Forecast, By Diagnosis 11.14.1. Blood Tests 11.14.2. Breath Tests 11.14.3. Stool Tests 11.14.4. Endoscopy 11.14.5. X-ray 11.14.6. CT scan 11.14.7. Others 11.15. Canada Dyspepsia Market Forecast, By End-User 11.15.1. Hospitals and clinics 11.15.2. Ambulatory surgical centers 11.15.3. Pharmacies 11.15.4. Diagnostic centers 11.15.5. Others 11.16. Canada Dyspepsia Market Forecast, By Treatment 11.16.1. Antacids 11.16.2. Antibiotics 11.16.3. H2 Blockers 11.16.4. Proton Pump Inhibitors (PPIs) 11.16.5. Prokinetics 11.16.6. Psychological Therapies 11.16.7. Others 11.17. Canada Dyspepsia Market Forecast, By Diagnosis 11.17.1. Blood Tests 11.17.2. Breath Tests 11.17.3. Stool Tests 11.17.4. Endoscopy 11.17.5. X-ray 11.17.6. CT scan 11.17.7. Others 11.18. North America Dyspepsia Market Attractiveness Analysis 11.18.1. By End-User 11.18.2. By Treatment 11.18.3. By Diagnosis 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Dyspepsia Market Analysis 12.1. Key Findings 12.2. Europe Dyspepsia Market Overview 12.3. Europe Dyspepsia Market Value Share Analysis, By End-User 12.4. Europe Dyspepsia Market Forecast, By End-User 12.4.1. Hospitals and clinics 12.4.2. Ambulatory surgical centers 12.4.3. Pharmacies 12.4.4. Diagnostic centers 12.4.5. Others 12.5. Europe Dyspepsia Market Value Share Analysis, By Treatment 12.6. Europe Dyspepsia Market Forecast, By Treatment 12.6.1. Antacids 12.6.2. Antibiotics 12.6.3. H2 Blockers 12.6.4. Proton Pump Inhibitors (PPIs) 12.6.5. Prokinetics 12.6.6. Psychological Therapies 12.6.7. Others 12.7. Europe Dyspepsia Market Value Share Analysis, By Diagnosis 12.8. Europe Dyspepsia Market Forecast, By Diagnosis 12.8.1. Blood Tests 12.8.2. Breath Tests 12.8.3. Stool Tests 12.8.4. Endoscopy 12.8.5. X-ray 12.8.6. CT scan 12.8.7. Others 12.9. Europe Dyspepsia Market Value Share Analysis, by Country 12.10. Europe Dyspepsia Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Dyspepsia Market Analysis, by Country 12.12. Germany Dyspepsia Market Forecast, By End-User 12.12.1. Hospitals and clinics 12.12.2. Ambulatory surgical centers 12.12.3. Pharmacies 12.12.4. Diagnostic centers 12.12.5. Others 12.13. Germany Dyspepsia Market Forecast, By Treatment 12.13.1. Antacids 12.13.2. Antibiotics 12.13.3. H2 Blockers 12.13.4. Proton Pump Inhibitors (PPIs) 12.13.5. Prokinetics 12.13.6. Psychological Therapies 12.13.7. Others 12.14. Germany Dyspepsia Market Forecast, By Diagnosis 12.14.1. Blood Tests 12.14.2. Breath Tests 12.14.3. Stool Tests 12.14.4. Endoscopy 12.14.5. X-ray 12.14.6. CT scan 12.14.7. Others 12.15. U.K. Dyspepsia Market Forecast, By End-User 12.15.1. Hospitals and clinics 12.15.2. Ambulatory surgical centers 12.15.3. Pharmacies 12.15.4. Diagnostic centers 12.15.5. Others 12.16. U.K. Dyspepsia Market Forecast, By Treatment 12.16.1. Antacids 12.16.2. Antibiotics 12.16.3. H2 Blockers 12.16.4. Proton Pump Inhibitors (PPIs) 12.16.5. Prokinetics 12.16.6. Psychological Therapies 12.16.7. Others 12.17. U.K. Dyspepsia Market Forecast, By Diagnosis 12.17.1. Blood Tests 12.17.2. Breath Tests 12.17.3. Stool Tests 12.17.4. Endoscopy 12.17.5. X-ray 12.17.6. CT scan 12.17.7. Others 12.18. France Dyspepsia Market Forecast, By End-User 12.18.1. Hospitals and clinics 12.18.2. Ambulatory surgical centers 12.18.3. Pharmacies 12.18.4. Diagnostic centers 12.18.5. Others 12.19. France Dyspepsia Market Forecast, By Treatment 12.19.1. Antacids 12.19.2. Antibiotics 12.19.3. H2 Blockers 12.19.4. Proton Pump Inhibitors (PPIs) 12.19.5. Prokinetics 12.19.6. Psychological Therapies 12.19.7. Others 12.20. France Dyspepsia Market Forecast, By Diagnosis 12.20.1. Blood Tests 12.20.2. Breath Tests 12.20.3. Stool Tests 12.20.4. Endoscopy 12.20.5. X-ray 12.20.6. CT scan 12.20.7. Others 12.21. Italy Dyspepsia Market Forecast, By End-User 12.21.1. Hospitals and clinics 12.21.2. Ambulatory surgical centers 12.21.3. Pharmacies 12.21.4. Diagnostic centers 12.21.5. Others 12.22. Italy Dyspepsia Market Forecast, By Treatment 12.22.1. Antacids 12.22.2. Antibiotics 12.22.3. H2 Blockers 12.22.4. Proton Pump Inhibitors (PPIs) 12.22.5. Prokinetics 12.22.6. Psychological Therapies 12.22.7. Others 12.23. Italy Dyspepsia Market Forecast, By Diagnosis 12.23.1. Blood Tests 12.23.2. Breath Tests 12.23.3. Stool Tests 12.23.4. Endoscopy 12.23.5. X-ray 12.23.6. CT scan 12.23.7. Others 12.24. Spain Dyspepsia Market Forecast, By End-User 12.24.1. Hospitals and clinics 12.24.2. Ambulatory surgical centers 12.24.3. Pharmacies 12.24.4. Diagnostic centers 12.24.5. Others 12.25. Spain Dyspepsia Market Forecast, By Treatment 12.25.1. Antacids 12.25.2. Antibiotics 12.25.3. H2 Blockers 12.25.4. Proton Pump Inhibitors (PPIs) 12.25.5. Prokinetics 12.25.6. Psychological Therapies 12.25.7. Others 12.26. Spain Dyspepsia Market Forecast, By Diagnosis 12.26.1. Blood Tests 12.26.2. Breath Tests 12.26.3. Stool Tests 12.26.4. Endoscopy 12.26.5. X-ray 12.26.6. CT scan 12.26.7. Others 12.27. Rest of Europe Dyspepsia Market Forecast, By End-User 12.27.1. Hospitals and clinics 12.27.2. Ambulatory surgical centers 12.27.3. Pharmacies 12.27.4. Diagnostic centers 12.27.5. Others 12.28. Rest of Europe Dyspepsia Market Forecast, By Treatment 12.28.1. Antacids 12.28.2. Antibiotics 12.28.3. H2 Blockers 12.28.4. Proton Pump Inhibitors (PPIs) 12.28.5. Prokinetics 12.28.6. Psychological Therapies 12.28.7. Others 12.29. Rest Of Europe Dyspepsia Market Forecast, By Diagnosis 12.29.1. Blood Tests 12.29.2. Breath Tests 12.29.3. Stool Tests 12.29.4. Endoscopy 12.29.5. X-ray 12.29.6. CT scan 12.29.7. Others 12.30. Europe Dyspepsia Market Attractiveness Analysis 12.30.1. By End-User 12.30.2. By Treatment 12.30.3. By Diagnosis 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Dyspepsia Market Analysis 13.1. Key Findings 13.2. Asia Pacific Dyspepsia Market Overview 13.3. Asia Pacific Dyspepsia Market Value Share Analysis, By End-User 13.4. Asia Pacific Dyspepsia Market Forecast, By End-User 13.4.1. Hospitals and clinics 13.4.2. Ambulatory surgical centers 13.4.3. Pharmacies 13.4.4. Diagnostic centers 13.4.5. Others 13.5. Asia Pacific Dyspepsia Market Value Share Analysis, By Treatment 13.6. Asia Pacific Dyspepsia Market Forecast, By Treatment 13.6.1. Antacids 13.6.2. Antibiotics 13.6.3. H2 Blockers 13.6.4. Proton Pump Inhibitors (PPIs) 13.6.5. Prokinetics 13.6.6. Psychological Therapies 13.6.7. Others 13.7. Asia Pacific Dyspepsia Market Value Share Analysis, By Diagnosis 13.8. Asia Pacific Dyspepsia Market Forecast, By Diagnosis 13.8.1. Blood Tests 13.8.2. Breath Tests 13.8.3. Stool Tests 13.8.4. Endoscopy 13.8.5. X-ray 13.8.6. CT scan 13.8.7. Others 13.9. Asia Pacific Dyspepsia Market Value Share Analysis, by Country 13.10. Asia Pacific Dyspepsia Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Dyspepsia Market Analysis, by Country 13.12. China Dyspepsia Market Forecast, By End-User 13.12.1. Hospitals and clinics 13.12.2. Ambulatory surgical centers 13.12.3. Pharmacies 13.12.4. Diagnostic centers 13.12.5. Others 13.13. China Dyspepsia Market Forecast, By Treatment 13.13.1. Antacids 13.13.2. Antibiotics 13.13.3. H2 Blockers 13.13.4. Proton Pump Inhibitors (PPIs) 13.13.5. Prokinetics 13.13.6. Psychological Therapies 13.13.7. Others 13.14. China Dyspepsia Market Forecast, By Diagnosis 13.14.1. Blood Tests 13.14.2. Breath Tests 13.14.3. Stool Tests 13.14.4. Endoscopy 13.14.5. X-ray 13.14.6. CT scan 13.14.7. Others 13.15. India Dyspepsia Market Forecast, By End-User 13.15.1. Hospitals and clinics 13.15.2. Ambulatory surgical centers 13.15.3. Pharmacies 13.15.4. Diagnostic centers 13.15.5. Others 13.16. India Dyspepsia Market Forecast, By Treatment 13.16.1. Antacids 13.16.2. Antibiotics 13.16.3. H2 Blockers 13.16.4. Proton Pump Inhibitors (PPIs) 13.16.5. Prokinetics 13.16.6. Psychological Therapies 13.16.7. Others 13.17. India Dyspepsia Market Forecast, By Diagnosis 13.17.1. Blood Tests 13.17.2. Breath Tests 13.17.3. Stool Tests 13.17.4. Endoscopy 13.17.5. X-ray 13.17.6. CT scan 13.17.7. Others 13.18. Japan Dyspepsia Market Forecast, By End-User 13.18.1. Hospitals and clinics 13.18.2. Ambulatory surgical centers 13.18.3. Pharmacies 13.18.4. Diagnostic centers 13.19. Others Japan Dyspepsia Market Forecast, By Treatment 13.19.1. Antacids 13.19.2. Antibiotics 13.19.3. H2 Blockers 13.19.4. Proton Pump Inhibitors (PPIs) 13.19.5. Prokinetics 13.19.6. Psychological Therapies 13.19.7. Others 13.20. Japan Dyspepsia Market Forecast, By Diagnosis 13.20.1. Blood Tests 13.20.2. Breath Tests 13.20.3. Stool Tests 13.20.4. Endoscopy 13.20.5. X-ray 13.20.6. CT scan 13.20.7. Others 13.21. ASEAN Dyspepsia Market Forecast, By End-User 13.21.1. Hospitals and clinics 13.21.2. Ambulatory surgical centers 13.21.3. Pharmacies 13.21.4. Diagnostic centers 13.21.5. Others 13.22. ASEAN Dyspepsia Market Forecast, By Treatment 13.22.1. Antacids 13.22.2. Antibiotics 13.22.3. H2 Blockers 13.22.4. Proton Pump Inhibitors (PPIs) 13.22.5. Prokinetics 13.22.6. Psychological Therapies 13.22.7. Others 13.23. ASEAN Dyspepsia Market Forecast, By Diagnosis 13.23.1. Blood Tests 13.23.2. Breath Tests 13.23.3. Stool Tests 13.23.4. Endoscopy 13.23.5. X-ray 13.23.6. CT scan 13.23.7. Others 13.24. Rest of Asia Pacific Dyspepsia Market Forecast, By End-User 13.24.1. Hospitals and clinics 13.24.2. Ambulatory surgical centers 13.24.3. Pharmacies 13.24.4. Diagnostic centers 13.24.5. Others 13.25. Others Rest of Asia Pacific Dyspepsia Market Forecast, By Treatment 13.25.1. Antacids 13.25.2. Antibiotics 13.25.3. H2 Blockers 13.25.4. Proton Pump Inhibitors (PPIs) 13.25.5. Prokinetics 13.25.6. Psychological Therapies 13.25.7. Others 13.26. Rest of Asia Pacific Dyspepsia Market Forecast, By Diagnosis 13.26.1. Blood Tests 13.26.2. Breath Tests 13.26.3. Stool Tests 13.26.4. Endoscopy 13.26.5. X-ray 13.26.6. CT scan 13.26.7. Others 13.27. Asia Pacific Dyspepsia Market Attractiveness Analysis 13.27.1. By End-User 13.27.2. By Treatment 13.27.3. By Diagnosis 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Dyspepsia Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Dyspepsia Market Overview 14.3. Middle East & Africa Dyspepsia Market Value Share Analysis, By End-User 14.4. Middle East & Africa Dyspepsia Market Forecast, By End-User 14.4.1. Hospitals and clinics 14.4.2. Ambulatory surgical centers 14.4.3. Pharmacies 14.4.4. Diagnostic centers 14.4.5. Others 14.5. Middle East & Africa Dyspepsia Market Value Share Analysis, By Treatment 14.6. Middle East & Africa Dyspepsia Market Forecast, By Treatment 14.6.1. Antacids 14.6.2. Antibiotics 14.6.3. H2 Blockers 14.6.4. Proton Pump Inhibitors (PPIs) 14.6.5. Prokinetics 14.6.6. Psychological Therapies 14.6.7. Others 14.7. Middle East & Africa Dyspepsia Market Value Share Analysis, By Diagnosis 14.8. Middle East & Africa Dyspepsia Market Forecast, By Diagnosis 14.8.1. Blood Tests 14.8.2. Breath Tests 14.8.3. Stool Tests 14.8.4. Endoscopy 14.8.5. X-ray 14.8.6. CT scan 14.8.7. Others 14.9. Middle East & Africa Dyspepsia Market Value Share Analysis, by Country 14.10. Middle East & Africa Dyspepsia Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Dyspepsia Market Analysis, by Country 14.12. GCC Dyspepsia Market Forecast, By End-User 14.12.1. Hospitals and clinics 14.12.2. Ambulatory surgical centers 14.12.3. Pharmacies 14.12.4. Diagnostic centers 14.12.5. Others 14.13. GCC Dyspepsia Market Forecast, By Treatment 14.13.1. Antacids 14.13.2. Antibiotics 14.13.3. H2 Blockers 14.13.4. Proton Pump Inhibitors (PPIs) 14.13.5. Prokinetics 14.13.6. Psychological Therapies 14.13.7. Others 14.14. GCC Dyspepsia Market Forecast, By Diagnosis 14.14.1. Blood Tests 14.14.2. Breath Tests 14.14.3. Stool Tests 14.14.4. Endoscopy 14.14.5. X-ray 14.14.6. CT scan 14.14.7. Others 14.15. South Africa Dyspepsia Market Forecast, By End-User 14.15.1. Hospitals and clinics 14.15.2. Ambulatory surgical centers 14.15.3. Pharmacies 14.15.4. Diagnostic centers 14.15.5. Others 14.16. South Africa Dyspepsia Market Forecast, By Treatment 14.16.1. Antacids 14.16.2. Antibiotics 14.16.3. H2 Blockers 14.16.4. Proton Pump Inhibitors (PPIs) 14.16.5. Prokinetics 14.16.6. Psychological Therapies 14.16.7. Others 14.17. South Africa Dyspepsia Market Forecast, By Diagnosis 14.17.1. Blood Tests 14.17.2. Breath Tests 14.17.3. Stool Tests 14.17.4. Endoscopy 14.17.5. X-ray 14.17.6. CT scan 14.17.7. Others 14.18. Rest of Middle East & Africa Dyspepsia Market Forecast, By End-User 14.18.1. Hospitals and clinics 14.18.2. Ambulatory surgical centers 14.18.3. Pharmacies 14.18.4. Diagnostic centers 14.18.5. Others 14.19. Rest of Middle East & Africa Dyspepsia Market Forecast, By Treatment 14.19.1. Antacids 14.19.2. Antibiotics 14.19.3. H2 Blockers 14.19.4. Proton Pump Inhibitors (PPIs) 14.19.5. Prokinetics 14.19.6. Psychological Therapies 14.19.7. Others 14.20. Middle East & Africa Dyspepsia Market Forecast, By Diagnosis 14.20.1. Blood Tests 14.20.2. Breath Tests 14.20.3. Stool Tests 14.20.4. Endoscopy 14.20.5. X-ray 14.20.6. CT scan 14.20.7. Others 14.21. Middle East & Africa Dyspepsia Market Attractiveness Analysis 14.21.1. By End-User 14.21.2. By Treatment 14.21.3. By Diagnosis 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Dyspepsia Market Analysis 15.1. Key Findings 15.2. South America Dyspepsia Market Overview 15.3. South America Dyspepsia Market Value Share Analysis, By End-User 15.4. South America Dyspepsia Market Forecast, By End-User 15.4.1. Hospitals and clinics 15.4.2. Ambulatory surgical centers 15.4.3. Pharmacies 15.4.4. Diagnostic centers 15.4.5. Others 15.5. South America Dyspepsia Market Value Share Analysis, By Treatment 15.6. South America Dyspepsia Market Forecast, By Treatment 15.6.1. Antacids 15.6.2. Antibiotics 15.6.3. H2 Blockers 15.6.4. Proton Pump Inhibitors (PPIs) 15.6.5. Prokinetics 15.6.6. Psychological Therapies 15.6.7. Others 15.7. South America Dyspepsia Market Value Share Analysis, By Diagnosis 15.8. South America Dyspepsia Market Forecast, By Diagnosis 15.8.1. Blood Tests 15.8.2. Breath Tests 15.8.3. Stool Tests 15.8.4. Endoscopy 15.8.5. X-ray 15.8.6. CT scan 15.8.7. Others 15.9. South America Dyspepsia Market Value Share Analysis, by Country 15.10. South America Dyspepsia Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Dyspepsia Market Analysis, by Country 15.12. Brazil Dyspepsia Market Forecast, By End-User 15.12.1. Hospitals and clinics 15.12.2. Ambulatory surgical centers 15.12.3. Pharmacies 15.12.4. Diagnostic centers 15.12.5. Others 15.13. Brazil Dyspepsia Market Forecast, By Treatment 15.13.1. Antacids 15.13.2. Antibiotics 15.13.3. H2 Blockers 15.13.4. Proton Pump Inhibitors (PPIs) 15.13.5. Prokinetics 15.13.6. Psychological Therapies 15.13.7. Others 15.14. Brazil Dyspepsia Market Forecast, By Diagnosis 15.14.1. Blood Tests 15.14.2. Breath Tests 15.14.3. Stool Tests 15.14.4. Endoscopy 15.14.5. X-ray 15.14.6. CT scan 15.14.7. Others 15.15. Mexico Dyspepsia Market Forecast, By End-User 15.15.1. Hospitals and clinics 15.15.2. Ambulatory surgical centers 15.15.3. Pharmacies 15.15.4. Diagnostic centers 15.15.5. Others 15.16. Mexico Dyspepsia Market Forecast, By Treatment 15.16.1. Antacids 15.16.2. Antibiotics 15.16.3. H2 Blockers 15.16.4. Proton Pump Inhibitors (PPIs) 15.16.5. Prokinetics 15.16.6. Psychological Therapies 15.16.7. Others 15.17. Mexico Dyspepsia Market Forecast, By Diagnosis 15.17.1. Blood Tests 15.17.2. Breath Tests 15.17.3. Stool Tests 15.17.4. Endoscopy 15.17.5. X-ray 15.17.6. CT scan 15.17.7. Others 15.18. Rest of South America Dyspepsia Market Forecast, By End-User 15.18.1. Hospitals and clinics 15.18.2. Ambulatory surgical centers 15.18.3. Pharmacies 15.18.4. Diagnostic centers 15.18.5. Others 15.19. Rest of South America Dyspepsia Market Forecast, By Treatment 15.19.1. Antacids 15.19.2. Antibiotics 15.19.3. H2 Blockers 15.19.4. Proton Pump Inhibitors (PPIs) 15.19.5. Prokinetics 15.19.6. Psychological Therapies 15.19.7. Others 15.20. Rest of South America Dyspepsia Market Forecast, By Diagnosis 15.20.1. Blood Tests 15.20.2. Breath Tests 15.20.3. Stool Tests 15.20.4. Endoscopy 15.20.5. X-ray 15.20.6. CT scan 15.20.7. Others 15.21. South America Dyspepsia Market Attractiveness Analysis 15.21.1. By End-User 15.21.2. By Treatment 15.21.3. By Diagnosis 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. AstraZeneca 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. GlaxoSmithKline 16.3.3. Takeda Pharmaceutical Company 16.3.4. Johnson & Johnson 16.3.5. Jiangsu Aosaikang Pharma 16.3.6. Eisai Co., Ltd. 16.3.7. Abbott Laboratories 16.3.8. Salix Pharmaceuticals 16.3.9. Bayer AG 16.3.10. Boehringer Ingelheim GmbH 16.3.11. Sanofi 16.3.12. Allergan Plc 16.3.13. Cadila Pharmaceuticals 16.3.14. Pfizer 17. Primary Key Insights

About This Report

Report ID67222
Category Healthcare
Published DateJuly 2020
No of Pages190
Contact Us